FHLC Fact Sheet

Fidelity MSCI Health Care Index ETF

$86.45
close, Nov 18, 2026

Over the year to Nov 18, 2026, FHLC returned +19.8% in total and charged 0.08% a year.

1-year total return	Expense ratio	Net assets	Net flow, 12 months to Jul 31, 2026
+19.8% VHT +19.7% to Nov 18, 2026	**0.08%** a year	**$4.0bn** on Oct 31, 2026	**+$288m** monthly N-PORT basis to Jul 31, 2026

Growth of $10,000, 1 year



FHLC **$11,981** +19.8% · VHT **$11,967** +19.7% · Total return, distributions reinvested, Nov 18, 2025 to Nov 18, 2026.

Returns

WINDOW	TOTAL RETURN
1 month	**+2.6%**
3 months	**+1.8%**
Year to date	**+17.6%**
1 year	**+19.8%**
3 years	**+50.1%**
5 years	**+40.7%**

Total return, distributions reinvested, each window to Nov 18, 2026.

Ten largest positions

HOLDING	WEIGHT
Eli Lilly & Co	**13.35%**
Johnson & Johnson	**8.93%**
AbbVie Inc	**6.42%**
UnitedHealth Group Inc	**5.44%**
Merck & Co Inc	**4.66%**
Thermo Fisher Scientific Inc	**3.09%**
Amgen Inc	**3.00%**
Abbott Laboratories	**2.66%**
Gilead Sciences Inc	**2.34%**
Pfizer Inc	**2.06%**

FHLC top ten by weight, 51.9% of the fund, of its 334 equity positions, from the holdings filed for Jul 31, 2026.

Facts

Equity fund · Tracks the MSCI USA IMI Health Care 25/50 Index · First traded Oct 24, 2013 · Benchmark MSCI USA IMI Health Care 25/50 Index, measured by VHT, which tracks the same index

ETFIQ is an independent publisher. Not an issuer, broker or adviser. No recommendations. Printed from etfiq.com/funds/fhlc.